Tau PET imaging: present and future directions

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand

(2017) Vladimir Stepanov et al.   NUCLEAR MEDICINE AND BIOLOGY

Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease

(2017) Leonel E. Rojo et al.   JOURNAL OF ALZHEIMERS DISEASE

Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer’s Disease Brain

(2016) Lisheng Cai et al.   ACS Chemical Neuroscience

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

(2016) Ruben Smith et al.   ACTA NEUROPATHOLOGICA

Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration

(2016) Corey T. McMillan et al.   ACTA NEUROPATHOLOGICA

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

Characterization of tau positron emission tomography tracer [ 18 F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

(2016) Kerstin Sander et al.   Alzheimers & Dementia

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

(2016) Hanna Cho et al.   ANNALS OF NEUROLOGY

AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies

(2016) Kejal Kantarci et al.   ANNALS OF NEUROLOGY

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology inMAPTmutation carriers

(2016) Ruben Smith et al.   BRAIN

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease

(2016) Elena Rodriguez-Vieitez et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Regional profiles of the candidate tau PET ligand18F-AV-1451 recapitulate key features of Braak histopathological stages

(2016) Adam J. Schwarz et al.   BRAIN

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

In vivoimaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET

(2016) Allan K. Hansen et al.   BRAIN

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging

(2016) Brian A. Gordon et al.   BRAIN

Cognitive resilience in clinical and preclinical Alzheimer’s disease: the Association of Amyloid and Tau Burden on cognitive performance

(2016) Dorene M. Rentz et al.   Brain Imaging and Behavior

Tau imaging with [18F]THK-5351 in progressive supranuclear palsy

(2016) A. Ishiki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351

(2016) Ryuichi Harada et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

(2016) Konstantinos Chiotis et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation

(2016) Ruben Smith et al.   JOURNAL OF ALZHEIMERS DISEASE

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease

(2016) Julian Dronse et al.   JOURNAL OF ALZHEIMERS DISEASE

Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease

(2016) Elena Rodriguez-Vieitez et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Synthesis and quality control of [18F]T807 for tau PET imaging

(2016) Daniel P. Holt et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)

(2016) Abbas M. Walji et al.   JOURNAL OF MEDICINAL CHEMISTRY

In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain

(2016) J. Sepulcre et al.   JOURNAL OF NEUROSCIENCE

Reference Tissue–Based Kinetic Evaluation of 18 F-AV-1451 for Tau Imaging

(2016) Suzanne L. Baker et al.   JOURNAL OF NUCLEAR MEDICINE

Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models

(2016) M. Brendel et al.   JOURNAL OF NUCLEAR MEDICINE

Kinetic Modeling of the Tau PET Tracer 18 F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects

(2016) Olivier Barret et al.   JOURNAL OF NUCLEAR MEDICINE

Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology

(2016) M. Jonasson et al.   JOURNAL OF NUCLEAR MEDICINE

Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease

(2016) S. Shcherbinin et al.   JOURNAL OF NUCLEAR MEDICINE

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles

(2016) E. D. Hostetler et al.   JOURNAL OF NUCLEAR MEDICINE

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy

(2016) Jennifer L. Whitwell et al.   MOVEMENT DISORDERS

Subcortical18F-AV-1451 binding patterns in progressive supranuclear palsy

(2016) Hanna Cho et al.   MOVEMENT DISORDERS

Increased basal ganglia binding of18F-AV-1451 in patients with progressive supranuclear palsy

(2016) Ruben Smith et al.   MOVEMENT DISORDERS

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Tau PET in Alzheimer disease and mild cognitive impairment

(2016) Hanna Cho et al.   NEUROLOGY

In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET

(2016) Akio Kikuchi et al.   NEUROLOGY

Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly

(2016) Jasmeer P. Chhatwal et al.   NEUROLOGY

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351

(2016) Samuel N. Lockhart et al.   PLoS One

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

(2016) Matthew R. Brier et al.   Science Translational Medicine

Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease

(2016) Laure Saint-Aubert et al.   Alzheimers Research & Therapy

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

(2016) Liang Wang et al.   JAMA Neurology

Heterogeneity in Suspected Non–Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals

(2016) Elizabeth C. Mormino et al.   JAMA Neurology

Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy

(2016) D L Dickstein et al.   Translational Psychiatry

[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation

(2016) W. Richard Bevan Jones et al.   Annals of Clinical and Translational Neurology

Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease

(2016) Gérard N. Bischof et al.   Annals of Clinical and Translational Neurology

Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807

(2016) Lieven Declercq et al.   Molecular Imaging

An autoradiographic evaluation of AV-1451 Tau PET in dementia

(2016) Val J. Lowe et al.   Acta Neuropathologica Communications

PART is part of Alzheimer disease

(2015) Charles Duyckaerts et al.   ACTA NEUROPATHOLOGICA

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

(2015) Marta Marquié et al.   ANNALS OF NEUROLOGY

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Synthesis of a PET tau tracer [ 11 C]PBB3 for imaging of Alzheimer’s disease

(2015) Min Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

(2015) Ryuichi Harada et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease

(2015) Rik Ossenkoppele et al.   HUMAN BRAIN MAPPING

PET Quantification of Tau Pathology in Human Brain with 11C-PBB3

(2015) Y. Kimura et al.   JOURNAL OF NUCLEAR MEDICINE

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease

(2015) R. Harada et al.   JOURNAL OF NUCLEAR MEDICINE

Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease

(2015) T. Tago et al.   JOURNAL OF NUCLEAR MEDICINE

Tau imaging: early progress and future directions

(2015) Victor L Villemagne et al.   LANCET NEUROLOGY

Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer

(2015) Tetsuro Tago et al.   MOLECULAR IMAGING AND BIOLOGY

PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies

(2015) Stephen N. Gomperts et al.   Neurodegenerative Diseases

Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue

(2015) Laetitia Lemoine et al.   Acta Neuropathologica Communications

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography

(2015) Aiko Ishiki et al.   PLoS One

Primary age-related tauopathy (PART): a common pathology associated with human aging

(2014) John F. Crary et al.   ACTA NEUROPATHOLOGICA

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy

(2014) Rik Ossenkoppele et al.   ANNALS OF NEUROLOGY

Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET

(2014) Nobuyuki Okamura et al.   BRAIN

Tau PET Imaging in Alzheimer’s Disease

(2014) Nobuyuki Okamura et al.   Current Neurology and Neuroscience Reports

In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease

(2014) Victor L. Villemagne et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers

(2014) M. Shah et al.   JOURNAL OF NUCLEAR MEDICINE

Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology

(2014) H. Hashimoto et al.   JOURNAL OF NUCLEAR MEDICINE

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury

(2014) E M Mitsis et al.   Translational Psychiatry

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

(2013) Chun-Fang Xia et al.   Alzheimers & Dementia

Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease

(2013) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

(2013) Masahiro Maruyama et al.   NEURON

Neuropathology of dementia in a large cohort of patients with Parkinson's disease

(2013) Judit Horvath et al.   PARKINSONISM & RELATED DISORDERS

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease

(2013) T. L. S. Benzinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome

(2013) Benjamin Lam et al.   Alzheimers Research & Therapy

Tau alternative splicing in familial and sporadic tauopathies

(2012) Michael Niblock et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology

(2012) Ryuichi Harada et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

(2011) Clifford R. Jack et al.   ANNALS OF NEUROLOGY

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

(2011) M. T. Fodero-Tavoletti et al.   BRAIN

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies

(2009) Paul W. Thompson et al.   JOURNAL OF NEUROCHEMISTRY

CSF biomarkers predict rate of cognitive decline in Alzheimer disease

(2009) M. I. Kester et al.   NEUROLOGY

PET radiotracers: crossing the blood–brain barrier and surviving metabolism

(2009) Victor W. Pike   TRENDS IN PHARMACOLOGICAL SCIENCES

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

(2008) Kurt A. Jellinger et al.   ACTA NEUROPATHOLOGICA

Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation

(2008) S. G. Lindquist et al.   EUROPEAN JOURNAL OF NEUROLOGY

Tau exon 10 alternative splicing and tauopathies

(2008) Fei Liu et al.   Molecular Neurodegeneration